Mateon Therapeutics Inc (MATN) Expected to Announce Earnings of -$0.11 Per Share
Equities analysts expect that Mateon Therapeutics Inc (NASDAQ:MATN) will report ($0.11) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Mateon Therapeutics’ earnings. Mateon Therapeutics reported earnings of ($0.12) per share during the same quarter last year, which indicates a positive year over year growth rate of 8.3%. The firm is scheduled to announce its next quarterly earnings report on Monday, November 13th.
On average, analysts expect that Mateon Therapeutics will report full year earnings of ($0.42) per share for the current year. For the next year, analysts expect that the company will report earnings of ($0.50) per share. Zacks’ EPS averages are an average based on a survey of sell-side analysts that follow Mateon Therapeutics.
Mateon Therapeutics (NASDAQ:MATN) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.03.
A number of brokerages have recently commented on MATN. Maxim Group set a $2.00 price objective on Mateon Therapeutics and gave the company a “buy” rating in a research report on Thursday, April 27th. Roth Capital assumed coverage on Mateon Therapeutics in a report on Thursday, April 20th. They issued a “buy” rating and a $2.00 target price for the company. Finally, Zacks Investment Research lowered Mateon Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 13th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $2.00.
Mateon Therapeutics (MATN) opened at 0.35955 on Friday. Mateon Therapeutics has a 12-month low of $0.27 and a 12-month high of $0.89. The firm’s market capitalization is $9.54 million. The stock has a 50 day moving average price of $0.34 and a 200-day moving average price of $0.53.
About Mateon Therapeutics
Mateon Therapeutics, Inc, formerly OXiGENE, Inc, is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.